Tumor Agnostic Education Center Disease State Hub

Tumor Agnostic

Education Center

News

‘Second Adjuvant’ Therapy With a BRAF/MEK Inhibitor Delayed Recurrence, Increased Toxicity Among Patients With BRAF-Mutated Melanoma

02/21/2024

Stephanie Holland ;

Study results demonstrated that ‘second adjuvant’ therapy with a BRAF/MEK inhibitor improved recurrence-free survival at the cost of toxicity among patients with BRAF-mutated melanoma who experienced disease recurrence after treatment with an...

Study results demonstrated that...

02/21/2024

Oncology

News

FDA Approves Encorafenib Plus Binimetinib for Metastatic BRAF V600E Non-Small Cell Lung Cancer

10/12/2023

Stephanie Holland ;

Based on findings from the PHAROS trial, the FDA has approved encorafenib plus binimetinib for adult patients with metastatic non-small cell lung cancer harboring a BRAF V600E mutation.

Based on findings from the...

10/12/2023

Oncology

Videos

Management of BRAF-Mutated Non-Small Cell Lung Cancer

09/26/2023

Lyudmila Bazhenova , MD;

At the Great Debates & Updates in Lung Cancer meeting in New York, New York, Lyudmila Bazhenova, MD, discussed developments and advances in the management of BRAF-mutated NSCLC.

At the Great Debates & Updates...

09/26/2023

Oncology

News

Addition of Binimetinib to Encorafenib Demonstrated Efficacy, Safety Among Patients With Advanced, Unresectable BRAFV600-Mutant Melanoma

09/11/2023

Stephanie Holland ;

According to results from part 2 of the phase 3 COLUMBUS trial, the addition of binimetinib to encorafenib improved progression-free survival, overall response rate, and had a favorable safety profile compared with encorafenib alone among...

According to results from part 2...

09/11/2023

Oncology

Josep Tabernero, MD, PhD, Vall d'Hebron Barcelona Hospital Campus

Videos

Sequencing of Encorafenib Plus Cetuximab Among Patients With BRAF-Mutant Metastatic Colorectal Cancer

08/25/2023

Josep Tabernero , MD, PhD;

At the 2023 World Congress on Gastrointestinal Cancers, Josep Tabernero, MD, PhD presented a post hoc analysis of the BEACON trial that evaluated differences among patients with BRAF V600E-mutant metastatic colorectal cancer treated with...

At the 2023 World Congress on...

08/25/2023

Oncology

Conference Coverage

Navitoclax Added to Dabrafenib-Trametinib Improved Response, Survival Among Patients With BRAF-Mutant Metastatic Melanoma

06/12/2023

Stephanie Holland ;

Findings of a phase 2 study presented at the 2023 ASCO Annual Meeting demonstrated the addition of navitoclax to dabrafenib and trametinib improved response and survival outcomes for patients with BRAF-mutant metastatic melanoma.

Findings of a phase 2 study...

06/12/2023

Oncology

Lyudmila Bazhenova, MD, Professor of Medicine at the University of California, San Diego, California

Videos

Dabrafenib Plus Trametinib for Patients With BRAF-V600E Mutated Lung Cancer

12/02/2022

Lyudmila Bazhenova, MD, reviews the treatment options for BRAF mutations in lung cancer, a topic she presented at the 2022 Great Debates & Updates in Lung Cancer meeting in New York.

Lyudmila Bazhenova, MD, reviews...

12/02/2022

Oncology

Recent News

News

Ipilimumab After PD-1 Inhibition Failure Among Patients With Metastatic Melanoma

11/05/2024

Allison Casey ;

A single-center real-world study found the use of ipilimumab in the second-line was an effective therapy for patients with metastatic BRAF/NRAS-wildtype metastatic melanoma without brain metastases.

A single-center real-world study...

11/05/2024

Oncology

News

Safety of Encorafenib Plus Binimetinib and Pembrolizumab for Advanced BRAF V600-Mutant Melanoma

10/31/2024

A safety lead-in for the STARBOARD trial found that both doses of encorafenib under evaluation, in combination with binimetinib and pembrolizumab, demonstrated safety that was comparable to the known profile for each agent.

A safety lead-in for the...

10/31/2024

Oncology

News

Encorafenib Plus Binimetinib for BRAF V600E-Mutant Advanced Non-Small Cell Lung Cancer in the First-Line Setting

10/08/2024

Allison Casey ;

According to phase 2 results, encorafenib plus binimetinib showed clinical activity for BRAF V600E-mutant advanced non-small cell lung cancer in the first-line setting.

According to phase 2 results,...

10/08/2024

Oncology

News

Vemurafenib for Pediatric Patients With Tumors Harboring BRAF V600 Mutations

08/09/2024

Allison Casey ;

Though the phase 2 MATCH trial was terminated early due to poor accrual, vemurafenib did appear to be tolerable and a potential treatment option among pediatric patients with tumors harboring BRAF-V600 mutations.

Though the phase 2 MATCH trial...

08/09/2024

Oncology

News

Adjuvant Dabrafenib Plus Trametinib Improved Long-Term Survival Among Patients With Advanced-Stage Melanoma Harboring BRAF V600 Mutations

07/11/2024

Stephanie Holland ;

According to final analysis results from the phase 3 COMBI-AD trial, adjuvant dabrafenib plus trametinib improved long-term recurrence-free and distant metastasis-free survival compared to placebo among patients with stage 3 melanoma...

According to final analysis...

07/11/2024

Oncology

News

Addition of Targeted Therapy Induction Phase to Combined Immunotherapy for Patients with BRAF-V600E/K Mutant Melanoma

06/20/2024

Allison Casey ;

According to a phase 2 study, there was no difference in PFS between a combined immunotherapy regimen and a targeted therapy induction followed by combined immunotherapy among patients with BRAF/V600E/K mutant melanoma.

According to a phase 2 study,...

06/20/2024

Oncology

News

FDA Grants Accelerated Approval to Tovorafenib for Patients With Relapsed or Refractory BRAF-Altered Pediatric Low-Grade Glioma

04/25/2024

Stephanie Holland

Based on results from the FIREFLY-1 trial, the FDA has granted accelerated approval to tovorafenib for patients aged 6 months and older with relapsed or refractory pediatric low-grade glioma harboring a BRAF fusion, rearrangement, or a BRAF...

Based on results from the...

04/25/2024

Oncology

News

‘Second Adjuvant’ Therapy With a BRAF/MEK Inhibitor Delayed Recurrence, Increased Toxicity Among Patients With BRAF-Mutated Melanoma

02/21/2024

Stephanie Holland ;

Study results demonstrated that...

02/21/2024

Oncology

News

FDA Approves Encorafenib Plus Binimetinib for Metastatic BRAF V600E Non-Small Cell Lung Cancer

10/12/2023

Stephanie Holland ;

Based on findings from the PHAROS trial, the FDA has approved encorafenib plus binimetinib for adult patients with metastatic non-small cell lung cancer harboring a BRAF V600E mutation.

Based on findings from the...

10/12/2023

Oncology

News

Addition of Binimetinib to Encorafenib Demonstrated Efficacy, Safety Among Patients With Advanced, Unresectable BRAFV600-Mutant Melanoma

09/11/2023

Stephanie Holland ;

According to results from part 2...

09/11/2023

Oncology

News

Intraoperative Radiation Therapy May Improve Survival For Certain Patients With Recurrent Cervical or Endometrial Cancer

11/14/2024

Allison Casey ;

According to a retrospective study, there was an appreciable survival gain for well-selected patients with recurrent or persistent endometrial or cervical cancer who receive intraoperative radiation therapy.

According to a retrospective...

11/14/2024

Oncology

News

Amrubicin Plus Irinotecan Demonstrates Promising Efficacy, Safety for Chemotherapy-Naïve Patients With Extensive-Disease Small Cell Lung Cancer

11/14/2024

Stephanie Holland ;

According to results from the phase 2 LC 08-01 trial, amrubicin plus irinotecan demonstrated promising efficacy and safety among chemotherapy-naïve patients with extensive-disease small cell lung cancer.

According to results from the...

11/14/2024

Oncology

News

Addition of Bempegaldesleukin to Nivolumab Does Not Benefit Cisplatin-Ineligible Patients With First-Line Advanced Urothelial Carcinoma

11/13/2024

Stephanie Holland ;

Results from the phase 2 PIVOT-10 trial demonstrated that the addition of bempegaldesleukin to first-line nivolumab did not improve outcomes for cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma.

Results from the phase 2...

11/13/2024

Oncology

News

Mirdametinib for Adult and Pediatric Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas

11/12/2024

Allison Casey ;

According to a phase 2b trial, mirdametinib demonstrated significant confirmed objective response rates with deep and durable reductions of volume of target plexiform neurofibromas and clinically meaningful improvements to health-related...

According to a phase 2b trial,...

11/12/2024

Oncology

News

Epirubicin Plus Cyclophosphamide and Docetaxel Reduces Long-Term Risk of Recurrence for Patients With TOP2A Normal Early Breast Cancer

11/12/2024

Stephanie Holland ;

According to final results from the DBCG 07-READ trial, the addition of epirubicin to cyclophosphamide and docetaxel reduced long-term risk of breast cancer recurrence among patients with TOP2A normal early breast cancer.

According to final results from...

11/12/2024

Oncology

News

Pembrolizumab Plus Chemotherapy For Patients With High-Risk Endometrial Cancer

11/11/2024

Allison Casey ;

According to results from a phase 3 trial, pembrolizumab plus chemotherapy did not improve DFS among patients with high-risk endometrial cancer. However, there may be a benefit among patients with mismatch report-deficient disease.

According to results from a...

11/11/2024

Oncology

FDA Approval

FDA Grants Approval to Obecabtagene Autoleucel for R/R B-Cell Precursor Acute Lymphoblastic Leukemia

11/08/2024

On November 8, 2024, the FDA approved CD19-directed genetically modified autologous T cell immunotherapy obecabtagene autoleucel for the treatment of patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia.

On November 8, 2024, the FDA...

11/08/2024

Oncology

News

Naporafenib in Combination With Rineterkib or Tremetinib for KRAS- or BRAF-Mutant Non-Small Cell Lung Cancer

11/07/2024

Allison Casey ;

While naporafenib plus rineterkib and naporafenib plus trametinib both had acceptable safety profiles, antitumor activity was limited among patients with KRAS-/BRAF-mutant non-small cell lung cancer.

While naporafenib plus...

11/07/2024

Oncology

News

Addition of Concurrent Thoracic Radiotherapy to First-Line TKI Therapy Improves Survival for Patients With EGFR-Mutated Non-Small Cell Lung Cancer

11/06/2024

Stephanie Holland ;

According to results from a phase 3 trial, the addition of concurrent thoracic radiotherapy to first-line icotinib improved survival among patients with EGFR-mutated oligo-organ metastatic non-small cell lung cancer.

According to results from a...

11/06/2024

Oncology

News

Ipilimumab After PD-1 Inhibition Failure Among Patients With Metastatic Melanoma

11/05/2024

Allison Casey ;

A single-center real-world study found the use of ipilimumab in the second-line was an effective therapy for patients with metastatic BRAF/NRAS-wildtype metastatic melanoma without brain metastases.

A single-center real-world study...

11/05/2024

Oncology